Boji Medical Technology Co

Boji Medical Technology Co FCF per Share

The Free Cash Flow per Share of Boji Medical Technology Co (300404.SZ) as of Oct 31, 2026 is 0.18 CNY. In the previous year, Free Cash Flow per Share was -0.01 CNY — a change of -2,748.94% (higher).

FCF per Share

0.18CNY

YoY

-2,748.94%

Last updated:

Free Cash Flow per Share of Boji Medical Technology Co is 2025 0.18 CNY. Free Cash Flow per Share of Boji Medical Technology Co was 2024 -0.01 CNY. It decreases by -2,748.94% higher compared to the previous year.

The Boji Medical Technology Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.06 CNY
Jan 1, 2019
-0.13 CNY
Jan 1, 2020
0.29 CNY
Jan 1, 2021
-0.09 CNY
Jan 1, 2022
-0.24 CNY
Jan 1, 2023
-0.07 CNY
Jan 1, 2024
-0.01 CNY
Jan 1, 2025
0.18 CNY
The Boji Medical Technology Co FCF per Share history
YEARFCF per ShareYoY
0.18CNY-2,748.94%
-0.01CNY-90.21%
-0.07CNY-71.75%
-0.24CNY+166.21%
-0.09CNY-131.54%
0.29CNY-325.72%
-0.13CNY+104.03%
-0.06CNY-33.50%
-0.09CNY-67.75%
-0.29CNY+835.27%
-0.03CNY-488.71%
0.01CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Boji Medical Technology Co Stock analysis

What does Boji Medical Technology Co do? Boji Medical Technology Co., Ltd. generates revenue through comprehensive CRO services for pharmaceutical and medical device development. The company offers preclinical research, clinical trials, data management, biostatistics, and regulatory consulting, primarily serving domestic pharmaceutical companies and research institutions. Their one-stop service model includes drug evaluation, medical device registration, and CDMO services for new drug and device production. The firm's domestic market focus ensures steady demand from local clients seeking regulatory compliance and R&D support. The company's revenue streams are derived from multiple service segments: preclinical studies, clinical research, and technology transfer. These services are tailored to meet the needs of pharmaceutical firms requiring outsourced R&D solutions. CDMO services further enhance their offerings by supporting manufacturing processes alongside development. Domestic clients form the core customer base, leveraging Boji's expertise in navigating China's regulatory landscape for drug and device approvals. Boji Medical Technology's business model centers on providing end-to-end CRO solutions, combining preclinical and clinical research with regulatory support. Their services are designed to accelerate product development cycles for clients, reducing time-to-market for new pharmaceuticals and medical devices. The firm's domestic market strategy aligns with the growing demand for R&D outsourcing within China's healthcare sector. Boji Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Boji Medical Technology Co stock

Free Cash Flow per Share of Boji Medical Technology Co is 0.18 CNY in 2025.

Free Cash Flow per Share of Boji Medical Technology Co changed from -0.01 CNY to 0.18 CNY, representing a -2,748.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Boji Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Boji Medical Technology Co

All Key Metrics — Boji Medical Technology Co